Navigation Links
Genaera Corporation Announces Third Quarter Financial Results
Date:11/9/2007

tock. The decrease in the nine-month period ended September 30, 2007, was due principally to decreases in stock-based compensation expense for stock options and restricted stock, partially offset by increases in costs associated with the departure of an executive in the current year.

The Company's cash, cash equivalents and short-term investment balance was $23.2 million at September 30, 2007.

"During the third quarter, both of our core assets, MEDI-528 for asthma and trodusquemine, or MSI-1436, for type 2 diabetes and obesity, progressed and remain on track with plan. Positive interim Phase 1 trodusquemine data announced in the quarter is another example of hitting stated milestones," said Jack Armstrong, President and Chief Executive Officer. "We continue to focus internal resources on the MSI-1436 program while maintaining control of our spending and remaining committed to meet our milestone targets to drive shareholder value."

About Genaera

Genaera Corporation is focused on advancing the science and treatment of metabolic diseases. The Company has significant market opportunities with a first-in-class molecule, trodusquemine (MSI-1436), that has the potential to redefine the treatment paradigm for obesity and type 2 diabetes and is presently in a Phase 1 trial in obesity. In addition, Genaera has a value- driven, fully out-licensed partnership with MedImmune, Inc. for a second core program that is presently undergoing Phase 2 clinical testing in asthma. Genaera is committed to directing resources to its core program and the aggressive clinical development of its key assets to build stockholder value. For further information, please see our website at http://www.genaera.com.

This announcement contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties, known and unknown. Forward-looking sta
'/>"/>

SOURCE Genaera Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Genaera Elects New Board Member and Announces Executive Appointments
2. Genaera to Present at Biotech 2007 and BIO InvestorForum
3. Memry Corporation Announces Preliminary Fiscal Fourth Quarter and 2007 Revenue
4. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
5. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
6. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
7. BioElectronics Corporation Announces Singapore and Malaysia Sales
8. Avicena Signs Worldwide Exclusive Distribution Agreement with RITA Corporation for its Proprietary Dermaceutical Compounds
9. DURECT Corporation to Present at the NewsMakers in the Biotech Industry Investment Conference
10. Insulet Corporation to Present at the Thomas Weisel Partners Healthcare Conference on September 6, 2007
11. Luminex Corporation to Present at Thomas Weisel Partners Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... , Aug. 19, 2014 CSSi, the leader ... recently announced the formation of the company,s Medical and ... the addition of Dr. William E. Gannon, Jr. ... http://photos.prnewswire.com/prnh/20140818/136957 The MCAB, with Dr. ... of therapeutic areas and set strategic goals for the ...
(Date:8/19/2014)... 19, 2014 /PRNewswire/ - iCo Therapeutics Inc. ("iCo" or ... results of its Oral Amphotericin B (Oral Amp ... study, conducted by ImmuneCarta®, the immune monitoring business ... effectiveness of Oral Amp B in reactivating latent ... despite intensive treatment with antiretroviral therapy. ...
(Date:8/18/2014)... Tampa, FL (Aug. 18, 2014) -- A new ... South Florida (USF) Morsani College of Medicine and ... the life-threatening complications of interventional cardiovascular disease treatment. ... model that the novel molecular therapy could selectively ... healing following a medical procedure using a balloon ...
(Date:8/18/2014)... Aug. 18, 2014   Sterne, Kessler, Goldstein & ... Washington, DC , announced today that ... Review (IPR) with the U.S. Patent and Trademark ... of BioReference Laboratories, Inc. (Nasdaq: BRLI).  These IPR petitions ... by Myriad Genetics, Inc. These patents have been asserted ...
Breaking Biology Technology:CSSi Appoints Dr. William E. Gannon, Jr. to Newly Formed Medical and Clinical Advisory Board 2CSSi Appoints Dr. William E. Gannon, Jr. to Newly Formed Medical and Clinical Advisory Board 3iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 2iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 3Selective therapy may improve artery repair after interventional cardiovascular procedures 2Selective therapy may improve artery repair after interventional cardiovascular procedures 3Sterne Kessler Files 11 IPR Petitions On Behalf Of GeneDx, Inc., Subsidiary Of BioReference Laboratories, Inc. 2Sterne Kessler Files 11 IPR Petitions On Behalf Of GeneDx, Inc., Subsidiary Of BioReference Laboratories, Inc. 3
... NOVATO, Calif., March 31 BioMarin,Pharmaceutical Inc. (Nasdaq ... (AnGes), BioMarin,s marketing and distribution partner in Japan, ... from the Japanese Ministry of Health, Labour and ... VI ( MPS,VI)., "We are proud to ...
... performance module implemented in just few months, organization kicks ... ... personal growth, OTTAWA, March ... employee performance and talent management software,today announced that Beaumont Hospitals ...
... March 31 Transave Inc.,reported today that its ... have the ability to penetrate mucus and,biofilms, and ... patients with cystic fibrosis, according to results of ... Results of the study titled "Biofilm penetration, ...
Cached Biology Technology:Naglazyme Approved by Japanese Ministry of Health 2Naglazyme Approved by Japanese Ministry of Health 3Naglazyme Approved by Japanese Ministry of Health 4Beaumont Hospitals in Michigan Selects Halogen Software for Pay for Performance System 2Study Confirms Anti-Infective ARIKACE(TM) Effectively Penetrates Mucus and Biofilm, and Kills Pseudomonas, a Bacteria Plaguing Cystic Fibrosis Patients 2Study Confirms Anti-Infective ARIKACE(TM) Effectively Penetrates Mucus and Biofilm, and Kills Pseudomonas, a Bacteria Plaguing Cystic Fibrosis Patients 3Study Confirms Anti-Infective ARIKACE(TM) Effectively Penetrates Mucus and Biofilm, and Kills Pseudomonas, a Bacteria Plaguing Cystic Fibrosis Patients 4
(Date:8/20/2014)... of 158 pregnant teenagers in Rochester, NY, nearly half ... of ice, cornstarch, vacuum dust, baby powder and soap, ... , Moreover, such teens had significantly lower iron levels ... substances. , Pregnant teens, regardless of pica, are at ... iron deficiency and anemia. Low iron in pregnant teens ...
(Date:8/20/2014)... , Aug. 20, 2014 /CNW/ -  Issue ... and can quickly become life threatening for some children.    ... as 1.2 million Canadians have food allergies and this number ... cent of children are estimated to have food allergies.  ... mild skin irritations and hives to breathing difficulties and loss ...
(Date:8/20/2014)... WORCESTER, MA Using population-based screening outcomes of approximately ... states, including four researchers at the University of Massachusetts ... combined immunodeficiency (SCID) can be successfully implemented across public ... programs published in the Aug. 20 issue of the ... JAMA ) showed the rate of SCID in newborns ...
Breaking Biology News(10 mins):Pica in pregnant teens linked to low iron 2Information Update - Allergens and food safety at school - What's in your child's lunch? 2Information Update - Allergens and food safety at school - What's in your child's lunch? 3Newborn screening expansion offers early diagnosis and treatment to infants with SCID 2Newborn screening expansion offers early diagnosis and treatment to infants with SCID 3
... 2007 Today, researchers report for the first ... that are inherited only from the motherare directly linked ... study, which highlights the role of mitochondrial genome variation ... in Genome Research ( www.genome.org ). ...
... (NPL) is part of Biotesting Europe, a new 358,000 ... will ensure that future testing procedures and facilities meet ... in this growing industry. Biometric recognition systems measure ... can be as varied as iris images, fingerprints, the ...
... smoking can be harmful, if not deadly. While the desire ... factors also play an important role. The etiology of these ... the environment. Adoption and twin studies have shown that the ... studies have provided evidence that ones sex can influence the ...
Cached Biology News:Scientists show that mitochondrial DNA variants are linked to risk factors for type 2 diabetes 2UK scientists working to help cut ID theft 2Does the desire to consume alcohol and tobacco come from our genetic makeup? 2Does the desire to consume alcohol and tobacco come from our genetic makeup? 3
LECHNER AND LaVECK MEDIUMfor the clonal growth of normal human bronchial and other epithelial cells. Requires additives. With glutamine.Recommended storage condition:oC to 8oCIntended use(s):research...
...
... Modules Highly efficient ... cloning into advanced λ ... For flexibility ... Systems, the modules of ...
... While antigen and antibody-based immunoaffinity ... been reused many times without compromising ... extremes and chaotropic agents has precluded ... Western blotting. The CHEMICON Re-Blot ...
Biology Products: